Patents Represented by Attorney, Agent or Law Firm Millen White Zelano & Branigan
  • Patent number: 8338395
    Abstract: Described are methods for providing prolonged physiologically acceptable steady state serum testosterone levels in a patient deficient in endogenous testosterone levels, methods for male contraception and methods for treating a disease or symptom associated with deficient endogenous levels of testosterone in a man, by intramuscularly administering testosterone esters in a vehicle.
    Type: Grant
    Filed: February 24, 2009
    Date of Patent: December 25, 2012
    Assignee: Bayer Intellectual Property GmbH
    Inventors: Doris Hubler, Sabine Fricke, Jan-Peter Ingwersen, Wilheim Kuhnz
  • Patent number: 8337787
    Abstract: A compact device for mixing fluids in a downflow reactor comprising at least one substantially horizontal gathering device provided with a vertical gathering line intended to receive the fluids, at least one injection device arranged in the gathering line, an annular mixing chamber located downstream from the gathering means in the direction of circulation of the fluids, the mixing chamber comprising an inlet end directly connected to the gathering line and an outlet end for passage of the fluids, and a horizontal predistribution plate comprising at least one chimney, the plate being located downstream from the mixing chamber at a distance d2, in the direction of circulation of the fluids. The reactor is especially useful for exothermic reactions, e.g. hydrotreatment, hydrodesulfurization, hydrodenitrogenation, hydrocracking, hydrogenation and hydrodearomatization reactions.
    Type: Grant
    Filed: November 19, 2010
    Date of Patent: December 25, 2012
    Assignee: IFP Energies Nouvelles
    Inventors: Frederic Augier, Denis Darmancier, Christophe Boyer
  • Patent number: 8336401
    Abstract: The invention relates to an accessory for a drilling apparatus for drilling holes into the ground and into which explosives can be filled for blasting purposes. Such drilling commonly occurs in open cast mining for mining of mineral deposits. It is known to take samples from materials blown from holes during drilling, permitting analysis of the samples in order to estimate accurately the mineral content in the area being mined. The accessory is operatively supported on a drilling apparatus and includes a dust particle catcher, for catching dust particles blown from a hole to form dust particle samples, and a collection arrangement including receptacles in which dust particle samples are collected. A control arrangement of the accessory controls the operation thereof and serves also to enable the hole and the depth region of the hole, from which each sample was collected, to be identified.
    Type: Grant
    Filed: July 13, 2007
    Date of Patent: December 25, 2012
    Inventor: Petrus Christiaan Gouws
  • Patent number: 8334137
    Abstract: Identified herein is the location of the MN protein binding site, and MN proteins/polypeptides that compete for attachment to vertebrate cells with immobilized MN protein. Such MN proteins/polypeptides prevent cell-cell adhesion and the formation of intercellular contacts. The MN protein binding site is a therapeutic target that can be blocked by organic or inorganic molecules, preferably organic molecules, more preferably proteins/polypeptides that specifically bind to that site. Therapeutic methods for inhibiting the growth of preneoplastic/neoplastic vertebrate cells that abnormally express MN protein are disclosed. Vectors are provided that encode the variable domains of MN-specific antibodies and a flexible linker polypeptide separating those domains. Further vectors are disclosed that encode a cytotoxic protein/polypeptide operatively linked to the MN gene promoter or a MN gene promoter fragment comprising the HIF-1 consensus binding sequence, and which vectors preferably further encode a cytokine.
    Type: Grant
    Filed: December 17, 2010
    Date of Patent: December 18, 2012
    Assignee: Bayer Healthcare LLC
    Inventors: Adrian L. Harris, Peter J. Ratcliffe
  • Patent number: 8334102
    Abstract: The invention teaches human-compatible monoclonal antibodies which are specific against human CD28 and human T-lymphocytes of several to all subgroups to activate without occupancy of an antigen receptor of the human T-lymphocytes and thus antigen-non-specifically.
    Type: Grant
    Filed: April 8, 2010
    Date of Patent: December 18, 2012
    Assignee: Theramab LLC
    Inventor: Thomas Hunig
  • Patent number: 8333913
    Abstract: A sputtering target including an oxide sintered body, the oxide sintered body containing indium (In) and at least one element selected from gadolinium (Gd), dysprosium (Dy), holmium (Ho), erbium (Er) and ytterbium (Yb), and the oxide sintered body substantially being of a bixbyite structure.
    Type: Grant
    Filed: February 28, 2008
    Date of Patent: December 18, 2012
    Assignee: Idemitsu Kosan Co., Ltd.
    Inventors: Kazuyoshi Inoue, Koki Yano, Masashi Kasami
  • Patent number: 8333906
    Abstract: The instant invention relates to mesogenic systems comprising a) a polymeric component, component A, obtained or obtainable from polymerization of a precursor comprising one or more mesogenic mono-reactive compounds, one or more di-reactive compounds, which optionally are also mesogenic compounds and optionally a photo-initiator and a low molecular weight component, component B, comprising one or more mono-reactive, mesogenic compounds, one or more mesogenic compounds and one or more chiral dopants, exhibiting a Blue Phase, as well as to the use of these systems in deices and to these devices.
    Type: Grant
    Filed: June 25, 2010
    Date of Patent: December 18, 2012
    Assignee: Merck Patent GmbH
    Inventors: Cecile Schott, John Patrick, Kevin Adlem, Louise Diane Farrand, Georg Bernatz, Achim Goetz, Peter Best, Herbert Plach
  • Patent number: 8334309
    Abstract: Novel heterocyclic indazole derivatives of the formula (I), in which L, Q, R, X, Y, R3, R4 and R5 have the meanings indicated in Claim 1, are SGK inhibitors and can be used for the treatment of SGK-induced diseases and complaints, such as diabetes, obesity, metabolic syndrome (dyslipidaemia), systemic and pulmonary hypertonia, cardiovascular diseases and kidney diseases, generally in fibroses and inflammatory processes of any type.
    Type: Grant
    Filed: April 18, 2008
    Date of Patent: December 18, 2012
    Assignee: Merck Patent Gesellschaft mit beschrankter Haftung
    Inventors: Markus Klein, Norbert Beier
  • Patent number: 8329692
    Abstract: Compounds selected from the group according to Claim 1 are inhibitors of tyrosine kinases, in particular of Met kinase, and can be employed, inter alia, for the treatment of tumours.
    Type: Grant
    Filed: July 4, 2008
    Date of Patent: December 11, 2012
    Assignee: Merck Patent Gesellschaft mit beschrankter Haftung
    Inventors: Oliver Schadt, Dieter Dorsch, Frank Stieber, Andree Blaukat
  • Patent number: 8329907
    Abstract: The present invention relates to compounds according to formula (I) as autotaxin inhibitors and the use of such compounds for the treatment and/or prophylaxis of physiological and/or pathophysiological conditions, which are caused, mediated and/or propagated by increased lysophosphatic acid levels and/or the activation of autotaxin, in particular of different cancers.
    Type: Grant
    Filed: March 9, 2010
    Date of Patent: December 11, 2012
    Assignee: Merck Patent GmbH
    Inventors: Melanie Schultz, Kai Schiemann, Wolfgang Staehle
  • Patent number: 8330147
    Abstract: An organic thin film transistor including a substrate having thereon at least three terminals of a gate electrode, a source electrode and a drain electrode, an insulator layer and an organic semiconductor layer, with a current between a source and a drain being controlled upon application of a voltage to the gate electrode, wherein the organic semiconductor layer includes a specified organic compound having an aromatic heterocyclic group in the center thereof; and an organic thin film light emitting transistor utilizing an organic thin film transistor, wherein the organic thin film transistor is one in which light emission is obtained utilizing a current flowing between the source and the drain, and the light emission is controlled upon application of a voltage to the gate electrode, and is made high with respect to the response speed and has a large ON/OFF ratio, are provided.
    Type: Grant
    Filed: November 28, 2007
    Date of Patent: December 11, 2012
    Assignee: Idemitsu Kosan, Co., Ltd.
    Inventors: Masatoshi Saito, Yuki Nakano, Hiroaki Nakamura
  • Patent number: 8329801
    Abstract: The invention provides a self-adhesive composition in powder form for the coating of metallic substrates, composed of homopolyamide (A) selected from PA11 and PA12, copolyamide (B), calcium carbonate and, optionally, at least one component selected from a pigment or dye, an anti-crater agent or spreading agent, a reductant, an antioxidant, a reinforcing filler, a UV stabilizer, a fluidizing agent and a corrosion inhibitor, said composition being devoid of silane-type adhesion promoter or of an adhesion promoter containing an epoxy, alcohol and/or carboxylic acid function, or derivatives thereof, and having a dry-state modulus and/or a wet-state modulus of greater than or equal to 2200 MPa [Standard NF EN ISO 527].
    Type: Grant
    Filed: September 7, 2007
    Date of Patent: December 11, 2012
    Assignee: Arkema France
    Inventors: Marc Audenaert, Jean-Charles Durand
  • Patent number: 8329974
    Abstract: The device described in the present invention can trap plugging particles contained in the liquid feed supplying a reactor functioning in gas and liquid co-current down-flow mode using a specific distributor tray comprising a filtration medium. The present device is of particular application to the selective hydrogenation of feeds containing acetylenic and dienic compounds.
    Type: Grant
    Filed: August 24, 2006
    Date of Patent: December 11, 2012
    Assignee: IFP Energies nouvelles
    Inventors: Abdelhakim Koudil, Christophe Boyer
  • Patent number: 8329698
    Abstract: The present invention relates to compounds of formula (I) wherein X, Y, Z, R1, R2, R3 are as defined in claim 1, including pharmaceutical compositions thereof and for their use in the treatment and/or prevention of diabetes, metabolic syndrome, obesity, cancer, inflammation.
    Type: Grant
    Filed: May 19, 2009
    Date of Patent: December 11, 2012
    Assignee: Merck Patent Gesellschaft mit Beschränkter Haftung
    Inventors: Daniel Cravo, Sophie Hallakou-Bozec, Franck Lepifre
  • Patent number: 8329787
    Abstract: Hindered amines represented by the general formula (I): (wherein R is an alkyl or hydroxyalkyl group having 1 to 30 carbon atoms or alkenyl having 2 to 30 carbon atoms; n is an integer of 1 to 4; when n is 1, R1 is alkyl having 1 to 22 carbon atoms, alkenyl having 2 to 22 carbon atoms, or a group represented by the general formula (III): (R is as defined above), while when n is 2 to 4, R1 is an n-valent organic group having 2 to 20 carbon atoms). When added to synthetic resins or coating materials, the amines can impart long-period stabilizing effect to the resins or the materials and exhibit excellent resistance to extraction with acid rain or chemicals.
    Type: Grant
    Filed: April 2, 2010
    Date of Patent: December 11, 2012
    Assignee: Adeka Corporation
    Inventors: Yoshinori Negishi, Takashi Ayabe, Etsuo Tobita
  • Patent number: 8329185
    Abstract: The invention relates to a method for quickly and effectively isolating and purifying five, namely the group 1, 2, 3, 10 and 13 allergens from grass pollen. The purification of said grass pollen is based on the inventive combination of hydrophobic interaction chromatography, gel filtration and cation exchange chromatography. The proteins obtained by the inventive method facilitate an improved diagnosis of pollen allergies and are used in pharmaceutical preparations for the therapy of pollenogenic diseases.
    Type: Grant
    Filed: December 13, 2007
    Date of Patent: December 11, 2012
    Assignee: Merck Patent Gesellschaft mit beschrankter Haftung
    Inventors: Roland Suck, Oliver Cromwell, Helmut Fiebig
  • Patent number: 8329408
    Abstract: The present invention also relates to biomarkers and the use of biomarkers for the prediction and prognosis of cancer as well as the use of biomarkers to monitor the efficacy of cancer treatment. Specifically, this invention relates to the use of HER-2, EGFR, VEGF, u-PA, p-PAI-1, and soluble forms thereof, as biomarkers for cancer, especially for subjects treated with sorafenib.
    Type: Grant
    Filed: October 30, 2006
    Date of Patent: December 11, 2012
    Assignee: Bayer Healthcare LLC
    Inventor: Scott Wilhelm
  • Patent number: 8329738
    Abstract: The invention relates to the use of imidazole derivatives of the formula (1): in which A, R?1, R?2 and R?3 are as defined in the description, as AMPK activators. The invention also relates to processes for the preparation of the said compounds, to their uses for the preparation of medicaments for the treatment of insulin resistance, diabetes and related pathologies, and also obesity, and to the pharmaceutical compositions comprising them. Certain compounds of the formula (1) are novel and, in this respect, also form part of the invention.
    Type: Grant
    Filed: June 12, 2007
    Date of Patent: December 11, 2012
    Assignee: Merck Patent Gesellschaft mit Beschränkter Haftung
    Inventors: Gerard Moinet, Dominique Marais, Sophie Hallakou-Bozec, Christine Charon
  • Patent number: 8323166
    Abstract: The present invention relates to a multi-functional pharmaceutical package surface and a method of preparing a multi-functional pharmaceutical package surface. In particular, the present invention relates to a pharmaceutical package having a protein deterrent and lubricious surface and methods of preparing said surface by applying coatings directly to the pharmaceutical package that (a) reduce the adsorption of proteins onto pharmaceutical packaging while not affecting the activity of the protein solution and (b) provide a lubricious surface. The pharmaceutical package surface may also contain a barrier coating. Coatings can be deposited on a variety of pharmaceutical packaging materials and configurations by various methods.
    Type: Grant
    Filed: January 9, 2007
    Date of Patent: December 4, 2012
    Assignee: Schott AG
    Inventors: Daniel Haines, Luis Burzio, Matthias Bicker, Horst Koller, Jasmina Marjanovic, Robert Hormes
  • Patent number: D673012
    Type: Grant
    Filed: November 4, 2011
    Date of Patent: December 25, 2012
    Assignee: Joseph Joseph Ltd.
    Inventors: Bill Holding, Ben Cox